CoChat

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Wang, Hui Qin, Mulford, Iain J., Sharp, Fiona, Liang, Jinsheng, Kurtulus, Sema, Trabucco, Gina, Quinn, David S., Longmire, Tyler A., Patel, Nidhi, Patil, Roshani, Shirley, Matthew D., Chen, Yan, Wang, Hao, Ruddy, David A., Fabre, Claire, Williams, Juliet A., Hammerman, Peter S., Mataraza, Jennifer, Platzer, Barbara, Halilovic, Ensar · 2021 · Cancer Research
Cited by 60

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

p53 is a transcription factor that plays a central role in guarding the genomic stability of cells through cell-cycle arrest or induction of apoptosis. However, the effects of p53 in antitumor immunity are poorly understood. To investigate the role of p53 in controlling tumor-immune cell cross-talk, we studied murine syngeneic models treated with HDM201, a potent and selective second-generation MDM2 inhibitor. In response to HDM201 treatment, the percentage of dendritic cells increased, including the CD103+ antigen cross-presenting subset. Furthermore, HDM201 increased the percentage of Tbet+Eomes+ CD8+ T cells and the CD8+/Treg ratio within the tumor. These immunophenotypic changes were eliminated with the knockout of p53 in tumor cells. Enhanced expression of CD80 on tumor cells was observed in vitro and in vivo, which coincided with T-cell–mediated tumor cell killing. Combining HDM201 with PD-1 or PD-L1 blockade increased the number of complete tumor regressions. Responding mice developed durable, antigen-specific memory T cells and rejected subsequent tumor implantation. Importantly, antitumor activity of HDM201 in combination with PD-1/PD-L1 blockade was abrogated in p53-mutated and knockout syngeneic tumor models, indicating the effect of HDM201 on the tumor is required for triggering antitumor immunity. Taken together, these results demonstrate that MDM2 inhibition triggers adaptive immunity, which is further enhanced by blockade of PD-1/PD-L1 pathway, thereby providing a rationale for combining MDM2 inhibitors and checkpoint blocking antibodies in patients with wild-type p53 tumors. Significance: This study provides a mechanistic rationale for combining checkpoint blockade immunotherapy with MDM2 inhibitors in patients with wild-type p53 tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-20-0189

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 60

Metadata

Authors
Wang, H. Q., Mulford, I. J., Sharp, F., Liang, J., Kurtulus, S., Trabucco, G., Quinn, D. S., Longmire, T. A., Patel, N., Patil, R., Shirley, M. D., Chen, Y., Wang, H., Ruddy, D. A., Fabre, C., Williams, J. A., Hammerman, P. S., Mataraza, J., Platzer, B., & Halilovic, E.
Venue
Cancer Research
Published
2021-01-27
Volume
81
Issue
11
Pages
3079-3091
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W3124390312
Cited by
60
References
14
FWCI
3.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. https://app.cochat.ai/papers/10.1158/0008-5472.can-20-0189
The paper
Wang, H. Q., Mulford, I. J., Sharp, F., Liang, J., Kurtulus, S., Trabucco, G., Quinn, D. S., Longmire, T. A., Patel, N., Patil, R., Shirley, M. D., Chen, Y., Wang, H., Ruddy, D. A., Fabre, C., Williams, J. A., Hammerman, P. S., Mataraza, J., Platzer, B., & Halilovic, E. (2021). Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer Research. https://doi.org/10.1158/0008-5472.can-20-0189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.